Methicillin-resistant Staphylococcus aureus bacteremia with elevated vancomycin minimum inhibitory concentrations.

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia poses a significant clinical challenge.
• Vancomycin remains a cornerstone therapy, but rising minimum inhibitory concentrations (MICs) can impact treatment efficacy.
• Understanding factors associated with elevated vancomycin MIC is crucial for optimizing patient outcomes.

Purpose of the Study:

• To characterize clinical features, treatments, and outcomes in patients with MRSA bacteremia and elevated vancomycin MIC (≥ 2 µg/mL).
• To identify patient-specific factors associated with vancomycin treatment challenges in MRSA bacteremia.
• To inform clinical decision-making for managing MRSA infections with reduced vancomycin susceptibility.

Main Methods:

• A case-control study design was employed.
• Cases comprised 25 patients with MRSA bacteremia and vancomycin MIC ≥ 2 µg/mL.
• Controls included 391 patients with MRSA bacteremia and vancomycin MIC < 2 µg/mL.

Main Results:

• Elevated vancomycin MIC was significantly associated with baseline hemodialysis.
• Prior MRSA colonization was a notable factor linked to higher vancomycin MIC.
• The presence of metastatic infection correlated with elevated vancomycin MIC.

Conclusions:

• Baseline hemodialysis, prior MRSA colonization, and metastatic infection are key clinical characteristics associated with elevated vancomycin MIC in MRSA bacteremia.
• These findings highlight patient subgroups that may require closer monitoring or alternative therapeutic strategies.
• Further research into management of MRSA with reduced vancomycin susceptibility is warranted.